Drug Profile
Concizumab - Novo Nordisk
Alternative Names: ALHEMO; Alhemo; Anti-TFPI monoclonal antibody; mAb-2021; NN-7415; NNC-0172-0000-2021; NNC-0172-2021; NNC-172-2021Latest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihaemorrhagics; Monoclonal antibodies
- Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Haemophilia A; Haemophilia B
- Phase II Haemophilia
Most Recent Events
- 09 Dec 2023 Pharmacodynamics, pharmacokinetics, efficacy and adverse events data from a phase III explorer8 trial in Haemophilia A and Haemophilia B presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Pooled efficacy data from the phase III explorer7 and explorer8 trials in Haemophilia A and B presented at 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Pooled efficacy data from the phase III explorer7 and explorer8 trials in Haemophilia A and B presented at 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)